Skip to main content
OpenTrials
Completed

NCT Number: NCT05071677

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

This study evaluates what influences treatment decision-making in African American women with triple negative breast cancer. The study also aims to learn about the influence of information sources that support this decision-making process.

Completed

Looking for future studies?

Notify Me

Key information

About this study

PRIMARY OBJECTIVE:

I. Evaluate the acceptance of treatment recommendations by African American women diagnosed with triple negative breast cancer (TNBC).

SECONDARY OBJECTIVES:

I. Evaluate the association of beliefs about chemotherapy, self-efficacy, and cancer-specific psychological distress with intention to follow through with treatment.

II. Evaluate the association of intention, Reliance on Formal or Informal Resources, and decisional conflict as predictors of final treatment decision.

III. Evaluate the association of Reliance on Formal or Informal Resources as a moderator of the relationship between intention and final treatment decision.

OUTLINE:

Patients participate in a standard of care treatment planning meeting over 3 hours with members of the multidisciplinary treatment team including, the oncologist, radiologist, oncology surgeon, and social worker. Patients then complete surveys over 20 minutes and within 30 days later. Some patients may participate in interviews over 30 minutes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New patient in the MD Anderson Cancer Center Nellie B. Connally Breast Center or Houston Area Locations (HALs) (presenting to the surgery clinic, medical oncology clinic, or multiteam clinic)
  • Women 18 years and older treated at MD Anderson Cancer Center between 1/1/2019 and 12/31/2021
  • Diagnosis of triple negative invasive breast cancer on percutaneous needle biopsy within 60 days of first clinic appointment demonstrated by estrogen receptor (ER) 0% (absence or very low presence of estrogen uptake), progesterone receptor (PR) 0% (absence or very low presence of progesterone uptake), and HER2 negative (immunohistochemistry [IHC] score of 0 or 1 or fluorescence in situ hybridization [FISH] non-amplified score 2.0 or less)
  • Tumor size >= 1 cm (chemotherapy is not recommended for tumors < 1 cm)
  • Breast cancer stage I, II, or III
  • Self-identify as of African descent (African American, African, Black, Afro-Caribbean, etc.)
  • Completion of treatment planning team meeting and receipt of treatment at MD Anderson or local oncologist under the guidance of MD Anderson medical oncologist; no time window for treatment completion
  • Ability to read, write, and speak in English, and provide consent

Exclusion criteria

  • Patients with previous history of breast cancer diagnosis
  • Patients with newly diagnosed bilateral breast cancer
  • Patients with psychiatric disorders that exceed moderate severity documented within patient medical record

Treatment and study plan

Discussion

Procedure

Participate in treatment planning meeting

Other names: Discuss

interview

Other

Participate in interview

Survey Administration

Other

Complete survey

Primary outcomes

  1. Proportion of patients who accept the recommended treatment plan

    Time frame: through study completion, an average of 1 year

    Patient demographics and clinical characteristics will be summarized using numerical summaries for continuous variables and proportions for categorical variables. The proportion of patients who accept the recommended treatment plan will be estimated along with a 95% confidence interval.

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Determinants of Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Oct 8, 2021
Registry last updated
Aug 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.